Company

Management Management

  • Management
  • Scientific Advisory Board
Samyang  has built a team of innovative and successful drug developers whose deep collective experience spans drug discovery, research, and development at leading biotechnology and pharmaceutical companies Samyang  has built a team of innovative and successful drug developers whose deep collective experience spans drug discovery, research, and development at leading biotechnology and pharmaceutical companies
Head of Samyang Holdings biopharmaceutical division, Lee Young-Joon Profile Image
Head of Samyang Holdings biopharmaceutical division
Lee Young-Joon

Lee Young-Joon graduated from Seoul National University College of Medicine, and completed both his master’s and doctorate degree in the same institute. He did his practice in laboratory medicine at Seoul National University Hospital and Samsung Medical Center and received his professional certification . He also held positions as the director of Laboratory Medicine at the National Cancer Center (NCC) Hospital and a member of the Institutional Review Board (IRB). In addition, he was awarded by the Minister of Health and Welfare for his contributions in the opening of the NCC and in the field of anticancer research. He conducted several research and development on molecular genetics, which are essential in diagnosing and treating various diseases, as well as research on cancer immunotherapy. He then entered the health and medical industry and lead the development and projects of Digital Healthcare and point of care testing (POCT) for infectious diseases. Moreover, he also has experience in leading project developments and clinical developments for new biopharmaceuticals in the biopharmaceutical industry. In 2021, he joined Samyang Holdings Pharmaceutical division and established the growth of anticancer drugs and medical devices, as well as global strategies for new biopharmaceuticals.

Biopharmaceutical Research Director Min-hyo Seo Profile Image.
Director of Biopharmaceuticals R&D Center Helen Cho

After earning her Bachelor’s degree from the Department of Biochemistry, Yonsei University and her Master’s degree in bioengineering from KAIST, Dr. Helen Cho acquired her PhD degree in molecular biology and biochemistry from the University of Medicine and Dentistry of New Jersey. Then, she completed her post-doctorate program at Salk Institute and joined Pfizer, a global pharmaceutical company, where she led the development of anticancer immunotherapy drugs based on combination therapy by using her experiences in various fields covering biological carriers and antibodies. As an Associate Research Fellow, she oversaw the research and development (R&D) of anticancer vaccines and oncolytic virus-based immunotherapy drugs as well as early clinical trials. Currently, she serves as the Director of Samyang Holdings Biopharmaceuticals Division R&D Center, supervising R&D in pharmaceuticals, biologics and MD businesses.

Chief Biopharmaceutical Officer Ho-Jun Choi Profile Image.
the director of the pharmaceutical business Lee Yong-jin

Director Lee Yong-jin obtained his Bachelor’s degree from the Department of Biology, Korea University and MBA from Dongguk University Business School. He joined the Samyang Group in 2001, served as Team Leader in Drug Development and Anticancer Drug Sales, and currently supervises pharmaceutical business in Samyang Holdings Biopharmaceuticals. With his career specializing in drug development, sales, and marketing that earned him commendations from the Minister of Health and Welfare and the Minister of Food and Drug Safety, he is overseeing international and Korean businesses.

Chief MD Officer Jae–Doo Lee Profile Image.
the director of MD business Lee Jae-Doo

The director, Lee Jae-doo, received his Bachelor's and Master's degree in chemical engineering from Hanyang University. He joined Samyang in 1993 and is currently working in the field of medical devices. After the release of the medical suture product in 1996, he was in charge of the overseas sales of the medical suture, and contributed greatly to establishing the company's global business base for the suture. Currently, he is directing sales, marketing and the MD plant in the medical device division.

  • Professor, Graduate School of Medical Science and Engineering, KAIST
  • CEO, PAIJIN BioScience
  • Eshelman School of Pharmacy,University of North Carolina at Chapel Hill.
  • Robert P. Pinkas Family Professor of Bioengineering, School of Engineering and Applied Sciences, Harvard University
  • Core Member, Wyss Institute for Biologically Inspired Engineering at Harvard University
  • Adjunct Investigator, Diabetes Endocrinology Research
  •  Eui-Cheol Shin, M.D.
    Eui-Cheol Shin, M.D.
  • JinKeon Pai, CEO
    JinKeon Pai, CEO
  • Professor, Graduate School of Medical Science and Engineering, KAIST
  • CEO, PAIJIN BioScience
  • Leaf. Huang, M.D.
    Leaf. Huang, M.D.
  • Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.

inquiry